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Association of G－33A Polymorphism in the Thrombo-
modulin Gene with Myocardial Infarction in Koreans
Hyun-Young PARK＊,＊＊, Toru NABIKA＊, Yangsoo JANG＊＊, Hyuck Moon KWON＊＊, 
Seung Yun CHO＊＊, and Junichi MASUDA＊
Thrombomodulin (TM), a thrombin receptor expressed on the endothelial surface, is known to play an im-
portant role in the anti-thrombogenic system in vivo. In this study, we examined the effects of 3 single-nu-
cleotide polymorphisms (SNPs) in the TM gene (G－33A, C1418T and C1922T) on the development of myo-
cardial infarction (MI) in Koreans. We found that G－33A was a common SNP (the minor allele frequency was
0.09) in Koreans. Eighty-five MI patients who had received coronary angiography were enrolled and were di-
vided into 3 groups according to the number of coronary arteries in which stenosis was found angiographi-
cally (1-vessel disease (1VD) to 3-vessel disease (3VD)). The criterion of coronary stenosis was 50% or more
stenosis on angiography. In addition, 102 controls (CONT) who had no significant stenosis were employed.
The number of AA/GA genotypes of G－33A was found to be significantly greater in the 1VD than in the
CONT ( p＝0.004 by Χ2-test) while no significant difference was found between the multivessel disease
(2–3VD) and the CONT. Multiple logistic analysis showed that G－33A was an independent risk factor for 
the 1VD with an odds ratio of 4.63 (95% confidence interval; 1.62–13.3). C1418T and C1922T were both in
linkage disequilibrium with G－33A; however, they were not independent risks for either the 1VD or the
2–3VD. A reporter gene assay showed that G－33A had a significant effect on the TM promoter activity. These
results indicated that G－33A polymorphism in TM might be a genetic risk factor for myocardial infarction. 
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genesis of MI. These observations raised the question of
whether more common polymorphisms in the TM gene
might have predisposing effects on MI in the general popula-
tion. And in fact, recent studies have indicated that such ge-
netic polymorphisms do have predisposing effects in MI;
Norlund et al. showed that a common single-nucleotide
polymorphism (SNP), C1418T, which results in Ala455 to Val
substitution, was associated with MI in their case-control
study (5). Ireland et al. found 3 SNPs in the 5´ -untranslated
region (5´ UTR) of the TM gene, one of which might be a
Introduction
Thrombomodulin (TM) is a thrombin receptor expressed on
the luminal surface of endothelial cells. The TM-thrombin
complex can activate protein C, which then acts as a potent
anticoagulant (1). Studies on mice without functional TM (2)
as well as on rare mutations in the TM gene reported in pa-
tients of myocardial infarction (MI) (3, 4) have suggested
that dysfunction of TM plays an important role in the patho-
risk for MI (6). According to the latter study, the three SNPs
may be more common in Asians than Caucasians, although
the authors did not provide precise frequencies of the poly-
morphisms in clearly defined ethnic populations. This obser-
vation prompted us to study TM polymorphisms in Koreans
with MI. In Korea, coronary artery diseases (CAD) are one
of the leading causes of premature death among the middle-
aged. Identification of a genetic predisposition to MI would
thus have a beneficial impact on its prevention in the Korean
population.
In this study, we newly identified an SNP in the 3´ -un-
translated region (3´ UTR) of the TM gene using the single-
strand conformation polymorphism (SSCP) method. Further,
we found that G－33A polymorphism in the 5´ UTR was
common in the Korean population and may be a risk factor
for a subpopulation of MI. We also demonstrated that this
polymorphism affects the TM promoter activity, suggesting
that it is functionally important.
Methods
Subjects
Eighty-six MI patients who had received coronary angiogra-
phy at the University Hospital of Yonsei University were re-
cruited. They were divided into 4 subgroups according to the
number of coronary arteries showing significant stenosis (0-
vessel disease (0VD) to 3-vessel disease (3VD))(Table 1).
The criterion of coronary stenosis was 50% or more stenosis
on angiography. Because only one MI patient with 0VD was
found, this patient and the 0VD subgroup were excluded
from the present study. As a control population (CONT), we
employed 102 patients who had neither significant coronary
stenosis (less than 30% stenosis on angiography) nor clinical
evidence of MI. Informed consent was obtained from all par-
ticipants. To estimate genotype frequencies in the general
Korean population, 291 subjects were employed as a refer-
ence population from participants of a health examination
done in the Seoul area. Because these subjects were anony-
mous, no clinical information on the reference population
was available. The study was approved by the ethical com-
mittee of Yonsei University College of Medicine.
Polymerase Chain Reaction (PCR)-SSCP
Genomic DNA was extracted from white blood cells using a
commercial kit. SSCP detection was done in 48 CAD pa-
tients as described previously (7, 8). Briefly, fifteen overlap-
ping fragments with sizes between 246 and 136 bps were
amplified by PCR using 32P-endlabeled primers. They cov-
ered 2,240 bp of the 5´ UTR and the exon of the TM gene.
PCR products were denatured by heating at 96ºC for 2 min
and then loaded onto 0.5% Mutation Detection Enhancement
(MDE) gel (FMC Bioproducts Co., Rockland, USA). Elec-
trophoresis was done at room temperature for 15–25 h at 5
W of constant power. Gels were dried and autoradiograms
were analyzed on a BAS 2500 system (Fujifilm, Tokyo,
Japan). PCR fragments showing polymorphism on SSCP
gels were then sequenced to identify the polymorphic sites.
Genotyping
Allele-specific oligonucleotide (ASO) hybridization was em-
ployed to genotype 3 SNPs in the TM gene. The primers and
conditions used for amplification are listed in Table 2. PCR
products were denatured in 200 µl of 0.4 eq/l NaOH and
transferred onto nylon membranes. The membranes were
then hybridized with 32P-endlabeled ASOs, and rinsed with
the buffer under the conditions indicated in Table 2. Autora-
diograms were analyzed using the BAS 2500 system.
Promoter Activity
Four constructs (pTM－355 with －33G or －33A, pTM
－125 with －33G or －33A) were made for the evaluation of
the TM promoter activity. Four PCR fragments of the TM
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Table 1. Demographic Data of Studied Populations
CONT(102) 1VD(30) 2VD(29) 3VD(25)
Age (years)＊ 55±10 56±9 57±11 61±10
Sex (% male)† 51.0 76.7 93.1 84.0
BMI (kg/m2) 24.3±3.9 24.3±3.6 24.2±5.6 24.4±2.4
Hypertension (%) 44.1 26.7 34.5 56.0
Diabetes mellitus (%)† 9.8 20.0 27.6 44.0
Smoking (%)† 27.5 73.3 86.2 68.0
TC (mg/dl) 187±41 203±39 201±44 198±36
HDL-C (mg/dl) 38.7±9.5 38.4±13.8 37.4±8.6 36.1±8.7
TG (mg/dl)‡ 149±92 145±60 185±94 152±58
CONT, control population; 1VD, 2VD, 3VD, 1-, 2-, 3-vessel disease, respectively; BMI, body-mass index; HDL-C, high-density
lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. ＊p＜0.05 between CONT and 3VD by one-way analysis of
variance (ANOVA). †p＜0.001 by χ2-test. ‡ p＜0.05 between CONT and 2VD by one-way ANOVA.
gene promoter spanning either －355 to 64 (pTM－355) or 
－125 to 64 (pTM－125) were obtained using genomic DNA
of AA or GG homozygotes for G－33A as templates. These
fragments were then cloned into the Picagene vector (Wako,
Tokyo, Japan).
Chinese hamster ovary (CHO) cells and bovine aortic en-
dothelial (BAE) cells were used for the reporter gene assay.
Cells were transfected with one of the four constructs de-
scribed above. The plasmid pcDNA3.1-LacZ was used in co-
transfection to estimate the transfection coefficiency. All the
transfection experiments were performed in triplicate. Cells
were plated at 105/well in 6-well plates and grown to a sub-
confluent state. Mixtures of the promoter constructs (0.8 µg)
and pcDNA3.1-LacZ (0.2 µg) were transfected using Lipo-
fectaminePlus (Gibco BRL, Gaithersburg, USA) following
the manufacturer’s instructions. Transfected cells were then
cultured for 48 h and luciferase activities were measured us-
ing the Luciferase Reporter Assay system (Promega, Madi-
son, USA). Luciferase activity was standardized with galac-
tosidase activity to correct the transfection efficiencies be-
tween the experiments.
Statistics
One-way analysis of variance (ANOVA) and χ 2-test were
used in the comparison of demographic data. Univariate
analysis of the genetic effects of SNPs was done using the
χ 2-test. Multivariate tests of risk factors were performed us-
ing logistic regression analysis with the SPSS package. Link-
age disequilibrium between SNPs was estimated as de-
scribed by Hill (9) and Thompson et al. (10).
Results
Clinical profiles of the subjects are shown in Table 1. A
higher age of onset and a higher prevalence of diabetes mel-
litus (DM) were observed in those with multivessel disease
(2–3VD) than in those with the 1VD.
Through the SSCP study, we identified a new SNP,
C1922T, in the 3´ UTR of the TM gene. In addition, we con-
firmed two SNPs, G－33A and C1418T (Ala155Val), in the
Korean population. Although several other nucleotide-sub-
stitutions in the TM gene have been reported in patients with
MI or venous thrombosis (2, 3, 11), we could not confirm
these mutations in the present cohort. In addition, the
－9/10AT and －133A alleles, which were identified in MI
patients by Ireland et al. (6), were not found on further
analysis of an additional 86 Koreans (46 MI and 40 refer-
ences) using direct sequencing. This result suggested that
these two nucleotide substitutions are rare in the Korean
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Table 2. PCR and Hybridization Conditions for ASO Genotyping
SNP PCR primers PCR condition＊ ASO＊＊ Hybridization Washing condition
temp.(ºC)
G－33A 5′-CCTTTTCCCGAACGTCC-3′ 1.0/60 G: 5′-TAAGTGCCCGGCCCTC-3′ 45 G: 2×SSC/0.2% SDS, 60ºC
5′-GCCTCTCCTGTCCGTCC-3′ A: 5′-GAGGGCCAGGCACTTA-3′ A: 2×SSC/0.2% SDS, 60ºC
C1418T 5′-CTAGCTCCGGGGTGTGC-3′ 1.0/65 C: 5′-GCCCTTGCCCGCCACA-3′ 45 C: 2×SSC/0.2% SDS, 60ºC
5′-CGCAGATGCACTCGAAGGT-3′ T: 5′-TGTGGCGGACAAGGGC-3′ T: 2×SSC/0.2% SDS, 60ºC
C1922T 5′-CTGGTGGTGGCGCTTTTGGC-3′1.0/65 C: 5′-CCTGGCTCCGTCC-3′ 35 C: 2×SSC/0.2% SDS, 45ºC
5′-CAAAGCTGGGGGTGAGGAGGCA-3′ T: 5′-CCTGGCTTCGTCC-3′ T: 2×SSC/0.2% SDS, 43ºC
PCR, polymerase chain reaction. ＊PCR condition is expressed as MgCl2 (mmol/l)/anneal temperature (°C). ASO, allele-specific
oligonucleotide. ＊＊Underlines indicate polymorphic nucleotides.
Table 3. Genotype Frequencies of 3 Single-Nucleotide Polymorphisms in the Thrombomodulin Gene
CONT 1VD 2VD 3VD REF
G－33A
GG 86 (84.3) 18 (60.0)＊ 22 (75.9) 20 (80.0) 247 (85.0)
GA/AA 16 (15.7) 12 (40.0)＊ 7 (24.1) 5 (20.0) 44 (15.0)
C1418T
CC 68 (66.7) 13 (43.3)† 15 (51.7) 17 (68.0) 175 (60.0)
CT/TT 34 (33.3) 17 (56.7)† 14 (48.3) 8 (32.0) 116 (40.0)
C1922T
CC 98 (96.1) 26 (86.7)‡ 28 (96.6) 24 (96.0) 186 (98.4)
CT/TT 4 (3.9) 4 (13.3)‡ 1 (3.4) 1 (4.0) 3 (1.6)
Values are n (%). CONT, the control population; 1VD, 2VD, 3VD, 1-, 2-, 3-vessel disease, respectively; REF, the reference popula-
tion. ＊ p＝0.004 vs. CONT and p＜0.001 vs. REF by χ 2-test. † p＝0.02 vs. CONT by χ 2-test. ‡ p＜0.001 vs. REF by χ 2-test.
population.
Among the SNPs studied, we found G－33A and C1418T
to be most common in the Korean population. The allele fre-
quencies of the minor alleles, －33A and 1418T, were 0.09
and 0.12, respectively, in the reference population. In con-
trast, the allele 1922T is much more rare (0.008) in Koreans.
These three SNPs were in strong linkage disequilibrium; the
allele －33A was almost exclusively associated with 1418T
(the coefficient of linkage disequilibrium was 0.972). The
coefficient of linkage disequilibrium between G－33A and
C1922T was 0.941, which indicated significant linkage dis-
equilibrium between these two SNPs as well.
The genotype frequencies of the three SNPs are shown in
Table 3. The observed genotype frequencies in all groups
were in Hardy-Weinberg’s equilibrium. The frequency of
AA/AG genotypes at －33 was significantly higher in the
1VD than in the CONT or the reference population (χ 2＝
8.2, p＝0.004 and χ 2＝11.7, p＜0.001, respectively) while
the 2VD and the 3VD showed genotype frequencies similar
to that of the CONT. The G－33A genotype frequency of the
CONT was not significantly different from that of the refer-
ence population. A similar tendency was observed for
C1418T and C1922T.
Multivariate analyses indicated that the －33A allele was
an independent risk factor for the 1VD, but not for the
2–3VD (Table 4). Among the other classical risk factors,
smoking was a common risk for both the 1VD and the
2–3VD, while serum cholesterol level, male sex, age, and di-
abetes mellitus (DM) were independent risks only for the
2–3VD. C1418T and C1922T were not independent risk fac-
tors for either the 1VD or the 2–3VD.
The activity of the TM promoter was studied using con-
structs possessing either G or A at －33. Both in BAE and
CHO cells, pTM－355 with －33A showed significantly less
luciferase activity than did pTM－355 with －33G (Fig. 1).
In contrast, the promoter activity was not significantly differ-
ent between pTM－125 with －33A and that with －33G.
Discussion
In this study, we showed that G－33A polymorphism in the
TM gene might be a risk factor for the 1VD. Further, we
provided in vitro evidence that this SNP itself is functional,
and affects the promoter activity.
Ireland et al. identified 3 SNPs, C－133A, G－33A and
GG－9/10AT, in the 5´ UTR of the TM gene (6). They found
6 of 208 individuals harboring one of these polymorphisms.
Interestingly, 5 of them were of Asian origin, even though
only 38 Asians were included in their study population (6).
This observation suggested that these polymorphisms were
more common in the Asian population than in Caucasians. In
the present study, however, we found that G－33A is a com-
mon polymorphism in the Korean population. The minor al-
lele frequency was 0.09 in our Korean cohort, similar to that
in Japanese (Park et al., unpublished data). In contrast, Ire-
land et al. found no occurrence of the －33A allele among
168 Caucasians. Le Flem et al. confirmed that －33A was
rare in Caucasians; they found only 3 heterozygotes among
600 individuals with and without venous thrombosis (12).
Therefore, G－33A is much more common in East Asian
populations than in Caucasians. This result emphasizes that
the ethnic background of the studied population should be
considered carefully when genetic risk factors for CAD are
evaluated. In contrast to G－33A, we could not identify the
－9/10AT or －133A allele in 190 Korean individuals either
by SSCP or direct sequencing, suggesting that these two nu-
cleotide-substitutions are very rare in Koreans. These two
mutations have therefore only a small impact on the general
Korean population even if they have potent predisposing ef-
fects.
Clinical and epidemiological observation distinguished the
1VD from the 2–3VD. The 2–3VD showed a higher age of
onset as well as a higher prevalence of DM (13–16). In ac-
cordance with these previous observations, we found that
age and DM were both independent risk factors for the
2–3VD (see Table 4). We thus propose that the 2–3VD pro-
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Table 4. Multiple Logistic Analyses of Risk Factors for the Single-Vessel (1VD) and the Multivessel Diseases (2–3VD)
β χ 2 p OR [95% confidence interval]
1VD
History of smoking 2.13 17.5 ＜0.0001 8.44 [3.10–22.9]
TM G－33A 1.53 8.03 0.005 4.63 [1.62–13.3]
2–3VD
Age 0.084 10.4 0.001 1.09 [1.03–1.14]
Sex 1.63 4.34 0.03 5.08 [1.11–23.6]
DM 1.60 8.24 0.004 4.97 [1.65–14.9]
History of smoking 2.11 12.5 0.0004 8.26 [2.53–26.8]
TC 0.018 7.71 0.006 1.02 [1.01–1.03]
Variables included in the analyses were age, sex, history of smoking, history of hypertension, history of diabetes mellitus (DM), body-
mass index, total cholesterol (TC), high-density lipoprotein cholesterol, triglyceride and thrombomodulin (TM) G－33A. OR, odds ratio.
gresses gradually without significant thrombotic accident in
its earlier stage. DM probably promotes arteriopathy, partic-
ularly in smaller arteries, in this process. By contrast, throm-
botic accidents may play a more critical role in the develop-
ment of the 1VD. In support of this idea, several studies have
pointed out that severe coronary stenosis was found less fre-
quently in younger patients of MI (13, 16). Our observation
raises the possibility that TM plays a major role in the devel-
opment of thrombosis before the multivessel disease be-
comes established. This idea is supported by the observation
that the prevalence of the AA/AG genotype in the younger
patients (below the median age of 58 years) with the 1VD
was as high as 50%, which was in marked contrast to that in
the 2–3VD (13%). Reduced TM activity, as suggested by the
in vitro promoter assay (see Fig. 1), in the local environment
of coronary arteries may accelerate thrombogenesis once
triggered, resulting in the occlusion of the coronary arteries.
However, as multiple factors are necessary prior to the de-
velopment of MI, MI incidence may still be lower in Kore-
ans than in Caucasians even though TM－33A is much more
frequent in the former population.
Recently, the concept of an acute coronary syndrome has
attracted much interest because it proposes an interpretation
based on MI without prior coronary stenosis (17, 18). During
this study, we found 5 patients with unstable angina or MI
without significant coronary stenosis. In three of these cases,
the patient was heterozygous for G－33A. Although this
number is too small to draw any conclusion, it may be inter-
esting to study the effect of TM G－33A on such a patholog-
ical condition.
The promoter assay revealed that －33A significantly de-
creased the TM promoter activity. This result basically con-
firmed the observation by Le Flem et al. (12), and seems
compatible with the association of －33A with MI; we can
expect that, with a lower level of expression of TM, the in-
travascular environment will tend to be thrombogenic. In
contrast to Le Flem et al., however, we found no significant
difference in the promoter activity when the shorter con-
structs were employed. This discrepancy might be due to dif-
ferences in the cell culture systems used in these experi-
ments. In addition, we might have missed small differences
in the activity, because the decrease of promoter activity was
only 15% in the previous study (12). Our results indicated
that the effect of G－33A was at least more obvious in the
longer construct than in the shorter one.
Yu et al. suggested that the TM promoter region between
－375 and －225 had domains binding with unknown trans-
acting factors (19). Tazawa et al. indicated that a similar re-
gion had an enhancer element that is different from Sp1
binding sites (20). G－33A itself or a protein binding to an
element including G－33A may interact, directly or indirect-
ly, with the putative trans-acting factors binding to this up-
stream region. Because of the lack of this interaction, we
might not be able to observe the difference between the
shorter constructs with －33G and A. It is known that TM
expression can be affected by shear stress as well as by 
several inflammatory cytokines, such as interleukin－1β and
tumor necrosis factor－α (21–23). Hence, it may be 
interesting to observe the effects of G－33A in cells stimulated
by these cytokines or by shear stress.
Numbers of studies have used association analysis to eval-
uate effects of genetic polymorphisms on heart diseases
(24–26). This analysis is, however, thought to be susceptible
to sampling biases (27). It is thus important to employ appro-
priate control populations. In this study, we employed a ref-
erence population to estimate the allele frequency of the
SNPs in the general Korean population. The frequency was
similar between CONT and the reference population, imply-
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Fig. 1. Luciferase assay using 4 different constructs for the
thrombomodulin promoter. Four different constructs con-
structed, one each with the promoter region between －355
and 64 (pTM－355) with －33G or A, and one each with the
promoter region between －125 and 64 (pTM－125) with
－33G or A. Each construct was transfected into Chinese
hamster ovary (CHO) cells or bovine aortic endothelial
(BAE) cells. The luciferase assay was performed in triplicate
and the galactosidase activity of cotransfected pcDNA3.1-
LacZ was used to correct transfection efficiencies between
the experiments. Columns and bars show the means±SD of
3 independent experiments.
ing that the observed difference in genotype frequencies be-
tween 1VD and CONT was not due to a bias in CONT.
However, the sample sizes were too small to draw conclu-
sive results. We are now collecting a larger cohort of CAD
to perform a replication study. Despite its limitations, our
case-control study together with the in-vitro study of the TM
promoter activity indicated that G－33A was a functional
polymorphism acting as a risk factor for MI.
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